WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'
Portfolio Pulse from Chris Katje
The WHO has announced a $135M strategic plan to combat the mpox outbreak, focusing on vaccination and prevention efforts. Companies like Bavarian Nordic, Emergent Biosolutions, GeoVax Labs, and SIGA Technologies, which are involved in mpox vaccines and treatments, have seen stock volatility.
August 26, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bavarian Nordic, involved in mpox vaccines, has experienced stock volatility due to WHO's strategic plan announcement.
Bavarian Nordic is directly involved in mpox vaccines, and the WHO's plan increases demand and attention on their products, likely boosting stock prices.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Emergent Biosolutions, with WHO-recommended mpox vaccines, sees stock volatility following WHO's funding announcement.
Emergent Biosolutions is a key player in mpox vaccines, and the WHO's strategic plan could lead to increased demand, positively impacting stock prices.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
GeoVax Labs, developing a mpox vaccine, has experienced stock volatility due to WHO's strategic plan announcement.
GeoVax Labs is developing a mpox vaccine, and the WHO's plan could increase interest and investment in their development efforts, likely boosting stock prices.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
SIGA Technologies, with mpox treatment Tpoxx, sees stock volatility following WHO's funding announcement.
SIGA Technologies' Tpoxx is a treatment for mpox, and the WHO's strategic plan could lead to increased demand for treatments, positively impacting stock prices.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70